Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)

Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)

Abstract In the phase II NIMBUS trial, patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) and high tumor mutational burden (TMB ≥ 9 mut/Mb) received nivolumab (3 mg/kg biweekly) and low-dose ipilimumab (1 mg/kg every 6 weeks) for 2 years or until pr...

Full description

Saved in:
Bibliographic Details
Main Authors: Romualdo Barroso-Sousa, Jorge Gomez Tejeda Zanudo, Tianyu Li, Sangeetha M. Reddy, Leisha A. Emens, Thomas M. Kuntz, Carolina Alves Costa Silva, Saud H. AlDubayan, Hoyin Chu, Beth Overmoyer, Paulina Lange, Molly K. DiLullo, Meagan Montesion, Julie Kasparian, Melissa E. Hughes, Victoria Attaya, Ameer Basta, Nancy U. Lin, Nabihah Tayob, Rinath Jeselsohn, Elizabeth A. Mittendorf, Sara M. Tolaney
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-59695-1
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items